This study evaluates the effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 outcomes within the US Veterans Affairs Healthcare System, finding 50–61% during XBB predominance and 24–35% effectiveness during JN.1 predominance, emphasizing the importance of strain match.
- Aisling R. Caffrey
- Haley J. Appaneal
- John M. McLaughlin